This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Keryx Biopharmaceuticals Inc (KERX)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 55.70M 14.68M 35.25M 28.41M
Receivables 0.00 0.00 7.00K 0.00
Inventories 0.00 0.00 0.00 0.00
Other Current Assets 1.23M 430.00K 534.00K 200.00K
Total Current Assets 56.93M 15.11M 40.00M 28.71M
Property, Plant & Equipment, Gross 1.23M 879.00K 855.00K 798.00K
Accumulated Depreciation & Depletion 877.00K 823.00K 788.00K 741.00K
Property, Plant & Equipment, Net 349.00K 56.00K 67.00K 57.00K
Intangibles 0.00 0.00 0.00 0.00
Other Non-Current Assets 281.00K 198.00K 209.00K 137.00K
Total Non-Current Assets 3.84M 3.46M 3.48M 3.40M
Liabilities & Shareholder Equity
Total Assets 60.77M 18.57M 43.49M 32.11M
Accounts Payable 14.00M 7.21M 8.87M 5.37M
Short Term Debt 0.00 0.00 0.00 0.00
Other Current Liabilities 0.00 0.00 0.00 0.00
Total Current Liabilities 15.33M 8.04M 9.77M 6.19M
Long Term Debt 0.00 0.00 0.00 0.00
Deferred Income Taxes 0.00 0.00 0.00 0.00
Other Non-Current Liabilities 38.00K 36.00K 2.67M 2.67M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 38.00K 36.00K 2.67M 2.67M
Total Liabilities 15.37M 8.08M 12.44M 8.87M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 45.40M 10.49M 31.05M 23.25M
Common Par 83.00K 72.00K 71.00K 62.00K
Additional Paid In Capital 485.01M 403.39M 401.22M 365.31M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -439.34M -392.61M -369.89M -341.76M
Treasury Stock -357.00K -357.00K -357.00K -357.00K
Other Equity Adjustments 0.00 0.00 0.00 0.00
Total Capitalization 45.40M 10.49M 31.05M 23.25M
Total Equity 45.40M 10.49M 31.05M 23.25M
Total Liabilities & Stock Equity 60.77M 18.57M 43.49M 32.11M
Total Common Shares Outstanding 82.64M 71.92M 71.02M 61.44M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 79.95K 79.95K 79.95K 79.95K
Basic Weighted Shares Outstanding 81.01M 71.63M 67.37M 58.99M
Diluted Weighted Shares Outstanding 81.01M 71.63M 67.37M 58.99M
Number of Employees 41 25 29 25
Number of Part-Time Employees 0 0 0 0
KERX News

KERX Keryx Biopharmaceuticals Inc

Analysts Ratings for KERX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 9 8 8 8
Moderate Buy 0 0 0 0
Hold 0 0 0 1
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 0
GET KERX ANALYST REPORT

Brokerage Partners

KERX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs